Tulobuterol
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 592568

CAS#: 41570-61-0

Description: Tulobuterol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells.

Chemical Structure

img
Tulobuterol
CAS# 41570-61-0
Instruction

Theoretical Analysis

MedKoo Cat#: 592568
Name: Tulobuterol
CAS#: 41570-61-0
Chemical Formula: C12H18ClNO
Exact Mass: 227.11
Molecular Weight: 227.732
Elemental Analysis: C, 63.29; H, 7.97; Cl, 15.57; N, 6.15; O, 7.03

Price and Availability

Size Price Availability Quantity
1g USD 340
5g USD 800
Bulk inquiry

Synonym: Tulobuterol

IUPAC/Chemical Name: 2-Chloro-alpha-(((1,1-dimethylethyl)amino)methyl)benzenemethanol

InChi Key: YREYLAVBNPACJM-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H18ClNO/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13/h4-7,11,14-15H,8H2,1-3H3

SMILES Code: OC(CNC(C)(C)C)C1=CC=CC=C1Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 227.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lin Q, Liu QH, Bao YX. [Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study]. Zhongguo Dang Dai Er Ke Za Zhi. 2013 Jun;15(6):462-5. Chinese. PubMed PMID: 23791063.

2: Yamaya M, Nishimura H, Nadine L, Kubo H, Ryoichi N. Tulobuterol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Physiol Rep. 2013 Aug;1(3):e00041. doi: 10.1002/phy2.41. Epub 2013 Aug 22. PubMed PMID: 24303127; PubMed Central PMCID: PMC3834998.

3: Ichikawa M, Kodama Y, Yoshimi K, Shiota S, Kotajima M, Nakajyo M, Seyama K, Fukuchi Y, Takahashi K. Effects of transdermal tulobuterol on dyspnea and respiratory function during exercise in patients with chronic obstructive pulmonary disease. J Thorac Dis. 2015 Apr;7(4):687-96. doi: 10.3978/j.issn.2072-1439.2015.04.22. PubMed PMID: 25973235; PubMed Central PMCID: PMC4419310.

4: Han X, Liu R, Ji L, Hui M, Li Q, Fang L, Bi K. Determination of tulobuterol in rat plasma using a liquid chromatography-tandem mass spectrometry method and its application to a pharmacokinetic study of tulobuterol patch. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jan 1;1008:108-114. doi: 10.1016/j.jchromb.2015.11.017. Epub 2015 Nov 28. PubMed PMID: 26638035.

5: Katsunuma T, Fujisawa T, Nagao M, Akasawa A, Nomura I, Yamaoka A, Kondo H, Masuda K, Yamaguchi K, Terada A, Ikeda M, Nishioka K, Adachi Y, Kurihara K. Effects of transdermal tulobuterol in pediatric asthma patients on long-term leukotriene receptor antagonist therapy: results of a randomized, open-label, multicenter clinical trial in Japanese children aged 4-12 years. Allergol Int. 2013 Mar;62(1):37-43. doi: 10.2332/allergolint.12-OA-0437. Epub 2012 Sep 25. PubMed PMID: 23000726.

6: Kim JH, Kim TH, Park HJ, Choi YJ, Kang JH, Song KH, Koo TS, Seo KW. The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, in Beagle dogs following transdermal and intravenous administration. Vet J. 2016 Feb;208:90-2. doi: 10.1016/j.tvjl.2015.10.012. Epub 2015 Oct 13. PubMed PMID: 26639828.

7: Tamura G, Ichinose M, Fukuchi Y, Miyamoto T. Transdermal tulobuterol patch, a long-actingβ(2)-agonist. Allergol Int. 2012 Jun;61(2):219-29. doi: 10.2332/allergolint.11-RA-0358. Epub 2012 Jan 25. Review. PubMed PMID: 22270072.

8: Sakamoto T, Fujimaki Y, Takada Y, Aida K, Terahara T, Kawanishi T, Hiyama Y. Non-destructive analysis of tulobuterol crystal reservoir-type transdermal tapes using near infrared spectroscopy and imaging. J Pharm Biomed Anal. 2013 Feb 23;74:14-21. doi: 10.1016/j.jpba.2012.10.003. Epub 2012 Oct 16. PubMed PMID: 23245228.

9: Izumi T, Hori S, Satoh H, Miki A, Sawada Y. [Questionnaire survey on the change of asthmatic response, adverse events and product usability due to drug switching between name-brand and generic tulobuterol tapes]. Yakugaku Zasshi. 2012;132(5):617-27. Japanese. PubMed PMID: 22687698.

10: Katsunuma T, Fujisawa T, Mizuho N, Akira A, Nomura I, Yamaoka A, Kondo H, Masuda K, Yamaguchi K, Terada A, Ikeda M, Nishioka K, Adachi Y, Kurihara K. Effects of Transdermal Tulobuterol in Pediatric Asthma Patients on Long-Term Leukotriene Receptor Antagonist Therapy: Results of a Randomized, Open-Label, Multicenter Clinical Trial in Japanese Children Aged 4-12 Years. Allergol Int. 2013;62(1):37-43. doi: 10.2332/allergolint.12-OA-0437. Epub 2015 Feb 27. PubMed PMID: 28942989.

11: Ichinose M, Seyama K, Nishimura M, Fukuchi Y, Nagai A, Mishima M, Kubo K; Beta-2 Agonist Research and Evaluation Committee in COPD (BAREC) Study Group. Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD. Respir Med. 2010 Feb;104(2):267-74. doi: 10.1016/j.rmed.2009.09.012. Epub 2009 Oct 28. PubMed PMID: 19875277.

12: Mochizuki H, Nanjo Y, Takahashi H. Better adherence to a transdermal tulobuterol patch than inhaled salmeterol in elderly chronic obstructive pulmonary disease patients. Geriatr Gerontol Int. 2013 Apr;13(2):398-404. doi: 10.1111/j.1447-0594.2012.00916.x. Epub 2012 Jul 23. PubMed PMID: 22817699.

13: Katsunuma T, Ohya Y, Fujisawa T, Akashi K, Imamura N, Ebisawa M, Daikoku K, Kondo N, Terada A, Doi S, Nishimuta T, Noma T, Hamasaki Y, Kurihara K, Masuda K, Yamada T, Yamada M, Yoshihara S, Watanabe K, Watanabe T, Kitabayashi T, Morikawa A, Nishima S; Protective Effect of Tulobuterol Patch on the Long-term Management of Asthma in Young Children Study Group. Effects of the tulobuterol patch on the treatment of acute asthma exacerbations in young children. Allergy Asthma Proc. 2012 May-Jun;33(3):e28-34. PubMed PMID: 22737706.

14: Le Bourgeois M, de Blic J, Chauvin JP, Scheinmann P, Paupe J. Treatment of asthma with tulobuterol or albuterol in school-age children. Clin Ther. 1990 Nov-Dec;12(6):513-9. PubMed PMID: 2289220.

15: Shindoh C, Tsushima R, Shindoh Y, Tamura G. Transdermal treatment with tulobuterol increases isometric contractile properties of diaphragm muscle in mice. Tohoku J Exp Med. 2007 Jul;212(3):309-17. PubMed PMID: 17592218.

16: Rhee YS, Kwon SY, Park CW, Choi NY, Byun WJ, Chi SC, Park ES. Characterization of monolithic matrix patch system containing tulobuterol. Arch Pharm Res. 2008 Aug;31(8):1029-34. doi: 10.1007/s12272-001-1264-8. Epub 2008 Sep 12. PubMed PMID: 18787793.

17: Nakamura A, Mori D, Tojo K. Evaluation of the predicted time-concentration profile of serum tulobuterol in human after transdermal application. Chem Pharm Bull (Tokyo). 2012;60(3):300-5. PubMed PMID: 22382408.

18: Kume H, Kondo M, Ito Y, Suzuki R, Yamaki K, Takagi K. Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function. Clin Exp Pharmacol Physiol. 2002 Dec;29(12):1076-83. PubMed PMID: 12390295.

19: Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kume H, Shimokata K. Comparison of the effects of tulobuterol patch and salmeterol in moderate to severe asthma. Clin Exp Pharmacol Physiol. 2006 Nov;33(11):1016-21. PubMed PMID: 17042908.

20: Dudley RE, Patterson SE, Machotka SV, Kesterson JW. One-month inhalation toxicity study of tulobuterol hydrochloride in rats and dogs. Fundam Appl Toxicol. 1989 Nov;13(4):694-701. PubMed PMID: 2576008.